Riskpilot← Back to searchSign inGet full accessEPS VASCULAR AB
NUFActiveOrg 921023863Hamnplanen 24, Se-263 62 VikenWholesale of pharmaceutical and medical goods · NACE 4646Est. 20181 employees
Revenue 2024
NOK 192,4M
+7% vs 2023
EBITDA margin
7.1%
+1% vs 2023
Equity ratio
60.4%
Financial strength
Net profit 2024
NOK 9,9M
+3% vs 2023
| Revenue | NOK 192,4M | +7% |
| EBITDA | NOK 13,7M | +1% |
| Net profit | NOK 9,9M | +3% |
| Total assets | NOK 77,3M | +10% |
| Equity | NOK 46,6M | -7% |
| Employees | 1 | — |
Legal name
EPS VASCULAR AB
Org number
921023863
Legal form
Norskregistrert Utenlandsk Foretak
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10. juli 2018
Share capital
—
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Hamnplanen 24, Se-263 62 Viken
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 126 094 | 144 388 | 144 388 | 180 307 | 192 374 |
| Staff expenses | −22 250 | −24 703 | −24 703 | −27 017 | −26 186 |
| EBITDA | 22 130 | 19 268 | 19 268 | 13 551 | 13 712 |
| Depreciation & amort. | −0 | −13 | −13 | −69 | −57 |
| EBIT | 22 130 | 19 256 | 19 256 | 13 482 | 13 655 |
| Net financials | −10 | 28 | 28 | 182 | 149 |
| Profit before tax | 22 120 | 19 284 | 19 284 | 13 664 | 13 804 |
| Tax | 4 053 | −0 | 3 557 | −0 | −0 |
| Net profit | 13 867 | 12 726 | 12 726 | 9 590 | 9 920 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 61 136 | 72 180 | 72 180 | 70 272 | 77 258 |
| Equity | 19 650 | 43 262 | 43 262 | 50 105 | 46 638 |
| Long-term debt | 22 886 | 28 918 | 0 | 0 | 0 |
| Short-term debt | 18 600 | 0 | 28 918 | 20 167 | 30 620 |
| Total debt | 41 486 | 28 918 | 28 918 | 20 167 | 30 620 |
EBITDA margin
7.1%
This company
15.8%
Market median
-55% vs market
20202024
Equity ratio
60.4%
This company
38.2%
Market median
+58% vs market
20202024
Return on equity
21.3%
This company
18.4%
Market median
+16% vs market
20202024
Net profit margin
5.2%
This company
8.1%
Market median
-36% vs market
20202024
Asset turnover
2.49×
This company
1.12×
Market median
+122% vs market
20202024
Debt / equity
0.66×
This company
0.62×
Market median
+6% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AC Contact Person | Contact Person | 2024 |
| Former (2) | ||
SB Contact Person | Contact Person | 2018 – 2022 |
AL Contact Person | Contact Person | 2022 – 2024 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EPS VASCULAR AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sindre Bjørgås Hagen | Contact Person | 0 companies |
| Aedin Ciara Murphy | Contact Person | 0 companies |
| Annette Lena Marie Davidsson | Contact Person | 0 companies |